KRYS
Krystal Biotech, Inc.
KRYS has the edge over UNH overall, supported by stronger fundamentals and stronger valuation.
UNH
UnitedHealth Group Incorporated
UNH has slightly lower modeled downside risk, despite its lower overall score.
KRYS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
KRYS's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
KRYS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $261 | -15% |
| Forward | 35x | $306 | — |
| Current | 42x | $306 | — |
| Fair | 44x | $321 | +5.1% |
| Expensive | 79x | $579 | +89% |
Historical ranges are pointers, not guarantees.
KRYS has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
KRYS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
KRYS has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
KRYS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.68 | +18% |
| Q3 2026 | $7.36 | +10% |
| Q2 2026 | $7.97 | +62% |
| Q1 2026 | $7.47 | +79% |
| Q4 2025 | $6.84 | +128% |
| Q3 2025 | $6.68 | +221% |
| Q2 2025 | $4.93 | +24% |
| Q1 2025 | $4.17 | +91% |
| Q4 2024 | $3.00 | +669% |
KRYS has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
KRYS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.3M | +30% |
| Q2 2026 | $119.2M | +24% |
| Q1 2026 | $116.4M | +32% |
| Q4 2025 | $107.1M | +18% |
| Q3 2025 | $97.8M | +17% |
| Q2 2025 | $96M | +37% |
| Q1 2025 | $88.2M | +95% |
| Q4 2024 | $91.1M | +116% |
KRYS has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 56% | +14 points |
| Q2 2026 | 49% | +8.1 points |
| Q1 2026 | 46% | +5.1 points |
| Q4 2025 | 41% | -4.1 points |
| Q3 2025 | 42% | +16 points |
| Q2 2025 | 41% | +29 points |
| Q1 2025 | 41% | +56 points |
| Q4 2024 | 45% | +38 points |
KRYS has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
KRYS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $90.3M | +138% |
| Q2 2026 | $71.2M | +40% |
| Q1 2026 | $73.2M | +196% |
| Q4 2025 | $75.4M | +45% |
| Q3 2025 | $38M | -34% |
| Q2 2025 | $50.8M | +$56.1M |
| Q1 2025 | $24.8M | +69% |
| Q4 2024 | $52M | +$61.1M |
KRYS has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
KRYS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +181K shares |
| 1 year | +3.4% | +1M shares |
| 3 years | +6.7% | +1.9M shares |
| 5 years | +39% | +8.6M shares |
| Available history | +94% | +14.9M shares |
KRYS has 31M diluted shares, up 3.4% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over KRYS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
KRYS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.5x | Net Cash |
| Q1 2025 | -2.7x | Net Cash |
| Q4 2024 | -4.8x | Net Cash |
KRYS has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
KRYS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.9 | Neutral |
| Stochastic | 31.3 | Neutral |
KRYS's weekly RSI is 46 (neutral) and its Stochastic is 31 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
KRYS PE vs Healthcare Sector
| Metric | KRYS | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 61% above |
| PE % | 42 | 29 | 13 pts above |
KRYS is trading at 42x earnings, a 61% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over KRYS on valuation relative to its sector.
KRYS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $320.8 | 4.7% below |
| 20 week MA | $336.9 | 9.3% below |
| 50 week MA | $300.8 | 1.6% above |
| 100 week MA | $231.7 | 32% above |
| 200 week MA | $184.5 | 66% above |
KRYS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 66% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over KRYS on trend strength, trading above more of its moving averages.
KRYS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $60.6 | +0.7% |
| 2021 | $60.6 | $72.3 | +19% |
| 2022 | $72.3 | $76.6 | +5.9% |
| 2023 | $76.6 | $124.1 | +62% |
| 2024 | $124.1 | $159.3 | +28% |
| 2025 | $159.3 | $252.2 | +58% |
| 2026 YTD | $252.2 | $305.7 | +21% |
KRYS has finished every year since 2020 higher, and it's up 21% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over KRYS on returns for 2026, with the stronger performance.